Aprea Therapeutics (APRE) CFO buys 5,700 shares and warrants
Rhea-AI Filing Summary
Aprea Therapeutics’ Senior Vice President and CFO John P. Hamill bought 5,700 shares of common stock in a private placement on January 30, 2026 at $0.89 per share, bringing his direct holdings to 33,433 shares.
He also received common warrants to purchase up to 5,700 additional shares at an exercise price of $0.765 per share. The warrants are immediately exercisable but include caps so his and his affiliates’ beneficial ownership cannot exceed 4.99% of common stock or 9.99% of total voting power after exercise. The warrants expire on the second anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144, assuming cashless exercise.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,700 shares
Net Buy
2 txns
Insider
Hamill John P.
Role
SrVP/CFO/Prin Fin & Acct Ofcr
Bought
11,400 shs ($5K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Warrant | 5,700 | $0.00 | $0.00 |
| Purchase | Common Stock | 5,700 | $0.89 | $5K |
Holdings After Transaction:
Common Warrant — 5,700 shares (Direct);
Common Stock — 33,433 shares (Direct)
Footnotes (3)
- F1. On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 5,700 shares of the Issuer's common stock (the "Shares") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the "Common Warrants") to purchase up to an aggregate of 5,700 Shares.
- F2. The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise.
- F3. The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Aprea Therapeutics (APRE) report for John P. Hamill?
Aprea Therapeutics reported that CFO John P. Hamill purchased 5,700 common shares in a private placement. He paid $0.89 per share and also received common warrants to buy up to 5,700 additional shares, increasing his direct equity exposure to the company.
What are the key terms of the Aprea Therapeutics warrants received by the CFO?
John P. Hamill received common warrants to purchase up to 5,700 Aprea shares at an exercise price of $0.765 per share. The warrants are immediately exercisable, subject to ownership limits, and give him the right to buy more shares on specified terms.
What ownership limits apply to the Aprea Therapeutics warrants held by the CFO?
The common warrants cannot be exercised if doing so would push Hamill and his affiliates above 4.99% of common stock outstanding or above 9.99% of total voting power. These caps limit how much voting and economic control can result from exercising the warrants.
When do the Aprea Therapeutics common warrants issued to the CFO expire?
The common warrants will expire on or before 5:00 p.m. New York City time on the second anniversary of the earlier of two events: effectiveness of a registration statement for the underlying shares or Rule 144 eligibility of those shares, assuming cashless exercise.
Was the Aprea Therapeutics CFO transaction a market purchase or a private placement?
The transaction occurred through a private placement, not open-market buying. Aprea entered a securities purchase agreement with accredited investors, including John P. Hamill, and sold him 5,700 common shares plus accompanying common warrants that closed on January 30, 2026.